Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia

Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid Leukemia

Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring <i>FLT3</i>-ITD display worse clinical outcomes. The integration and advancement of FLT3 TKI in AML treatment provided significant therapeut...

Full description

Bibliographic Details
Main Authors: Javier Bregante, Anna Schönbichler, Daniel Pölöske, Lina Degenfeld-Schonburg, Garazi Monzó Contreras, Emir Hadzijusufovic, Elvin D. de Araujo, Peter Valent, Richard Moriggl, Anna Orlova
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
acute myeloid leukemia
tyrosine kinase inhibitor
FMS-like tyrosine kinase 3
targeted therapy
ponatinib
cabozantinib
Online Access:https://www.mdpi.com/2072-6694/13/24/6181

Internet

https://www.mdpi.com/2072-6694/13/24/6181

Similar Items